title: D-ribose aids heart failure patients with preserved ejection fraction and diastolic dysfunction: a pilot study.
abstract: OBJECTIVE
  The incidence of heart failure continues to escalate with >550,000 newly diagnosed patients annually worldwide. More than half of the patients with heart failure have preserved ejection fraction or isolated diastolic dysfunction, for which no current effective therapies for diastolic dysfunction exist. Every cell requires adequate levels of high energy phosphates to maintain integrity and function. Previous studies have demonstrated that diastolic function is energy dependent and supplemental D-ribose has shown to improve diastolic dysfunction. This study investigated what role D-ribose might play in congestive heart failure patients with preserved systolic function and diastolic dysfunction.
  
  
  METHODS
  A total of 11 patients, New York Heart Association class II-IV, with clinical symptoms, normal left ventricular systolic function and echocardiographic evidence of diastolic dysfunction were enrolled after meeting inclusion criteria. Each patient received oral D-ribose (5 g/dose) for 6 weeks. Echocardiographic evaluation, cardiopulmonary metabolic testing and subjective questionnaire assessment were performed at baseline, 6 weeks and at 9 weeks (3 weeks after discontinuing D-ribose).
  
  
  RESULTS
  An improvement in their tissue Doppler velocity (E'), which was maintained at 9 weeks, was demonstrated in 64% of the patients. Five patients showed an improvement in their ratio of early diastolic filling velocity (E) to early annulus relaxation velocity (E'). There was no appreciable difference in these measurements during valsalva or with leg raising and handgrip exercises. Four patients also had an improvement in their maximum predicted VO2 values; two demonstrated a worsening effect and no differences were noted in the remaining patients. Subjective assessment revealed a benefit in only one patient, worsening symptoms in one patient and no change in the remaining cohort.
  
  
  CONCLUSIONS
  This pilot study revealed some beneficial trends with D-ribose even with this small cohort size. However, future investigations are necessary to further substantiate these observed benefits.
authors.affiliation: Cardiovascular Medicine, Ohio State University, Columbus, OH, USA.
authors.forename: Melike
authors.initials: M
authors.lastname: Bayram
authors.affiliation: Jacqmar, Inc., 10965 53rd Ave. No., Plymouth, MN 55442, USA congenital@aol.com.
authors.forename: J A
authors.initials: JA
authors.lastname: St Cyr
authors.affiliation: Cardiovascular Medicine, Ohio State University, Columbus, OH, USA.
authors.forename: William T
authors.initials: WT
authors.lastname: Abraham
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D003971:Diastole / Q000502:physiology*; D004452:Echocardiography; D005260:Female; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D012266:Ribose / Q000008:administration & dosage / Q000627:therapeutic use*; D013318:Stroke Volume / Q000502:physiology*
chemical_list: D012266:Ribose
keywords:     d-ribose; diastolic dysfunction; heart failure; preserved systolic function